Summary
0.69
0.02
(3.70%)
07/21/2026
Arcadia Biosciences, Inc. (RKDA)Key Facts
Performance
Historical returns1D
3.70%
1W
6.94%
1M
n/a
3M
-40.54%
6M
-71.17%
1Y
-85.40%
5Y
-99.33%
Snapshot
Key statisticsClose
0.69
Change
0.02
Change %
3.70%
Open
0.66
Day Range
0.66 – 0.69
Volume
23,935
Avg Vol (20d)
91,393
Rel Vol
0.26x
52W Range
0.60 - 6.71
vs 52W High
-89.75%
vs 52W Low
15.53%
Gap
0.02
Market Cap
USD 5.03M
Beta
0.57
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
New Highs
Historical highs| Period | New Highs | From Last |
|---|---|---|
| 5-Day | 1× | -0.03% |
| 1-Month | 0× | -10.95% |
| 3-Month | 1× | -42.71% |
| 6-Month | 0× | -70.11% |
| YTD | 4× | -75.00% |
| Period | New Highs | From Last |
|---|---|---|
| 52-Week | 5× | -87.45% |
| 2-Year | 13× | -89.26% |
| 3-Year | 7× | -89.26% |
| 5-Year | 0× | -99.39% |
| 10-Year | 2× | -99.97% |
Financial SnapshotFY 2025
Full financialsRevenue
USD 4.86M
-3.7% YoY
Net Income
-USD 2.34M
-45.8% YoY
EPS
-1.71
-66.9% YoY
Gross Margin
36.2%
Operating Margin
-205.7%
Net Margin
-48.1%
EBITDA
-USD 9.96M
Free Cash Flow
-USD 4.74M
-97.6% margin
ROE
-56.5%
ROA
-35.7%
Debt / Equity
0.00x
net debt -USD 259.00K
Cash & Equiv.
USD 259.00K
Fundamental Ratings
MainC-
RecommendedStrong Sell
DCFStrong Sell
ROEStrong Sell
ROAStrong Sell
Debt/EquityStrong Sell
P/EStrong Sell
P/BBuy
Latest Earnings
- RKDA reported last earnings on 2026-05-14.
- EPS of $-2.11 vs $-0.8 estimated — surprise $-1.31.
- Revenue of $1M vs $2M estimated — surprise $-1M.
News
All newsArcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc. (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496...
Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc. (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today that it has entered into securities purchase agreements for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded...
Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights
-- Zola ® volumes increase 18% year-over-year -- -- SG&A at lowest level in Arcadia's history -- DALLAS, May 14, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the...
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights
-- Zola ® revenues increase 17% year-over-year -- -- Arcadia and Roosevelt Resources terminate proposed business combination --
Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds
DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that it has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options to purchase...
Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources
DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that on December 24, 2025, it received a notice from Roosevelt Resources, LP, terminating the Securities Exchange Agreement between Arcadia...
Arcadia Biosciences (NASDAQ:RKDA) Shares Cross Below Fifty Day Moving Average – Here’s Why
Arcadia Biosciences, Inc. (NASDAQ: RKDA - Get Free Report) passed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $3.81 and traded as low as $3.59. Arcadia Biosciences shares last traded at $3.6190, with a volume of 5,250 shares traded. Analysts...
Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights
-- Zola ® year-to-date revenues increase 26% year over year -- -- Arcadia gross profit margins exceed 30% for 11 th straight quarter -- -- Arcadia cash balance declines by only $257K to $1.1M -- DALLAS, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and...
Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business Highlights
-- Arcadia revenues increase 11% year over year driven by 24% growth in Zola ® -- -- Arcadia receives 2.7 million shares of stock in ABVE --
Arcadia Biosciences, Inc. (RKDA) Q1 2025 Earnings Call Transcript
Arcadia Biosciences, Inc. (NASDAQ:RKDA ) Q1 2025 Earnings Conference Call May 8, 2025 2:00 PM ET Company Participants Mark Kawakami - Chief Financial Officer T.J. Schaefer - President and Chief Executive Officer Conference Call Participants Ben Klee - Lake Street Operator Hello, and welcome to...
Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights
-- Revenues increase 22% year over year driven by 90% growth in Zola ® -- -- Arcadia sells patents for $750K and eliminates $1M in liabilities -- -- Roosevelt agreement amended to provide greater certainty regarding exchange ratio -- DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences,...
Arcadia Biosciences (RKDA) Announces Date of First Quarter 2025 Financial Results and Business Highlights Conference Call
Arcadia Biosciences, Inc.® (Nasdaq: RKDA) will release its financial and business results for the first quarter of 2025 on May 8, 2025 at 2:00 p.m. ET.
Arcadia Biosciences, Inc (RKDA) Q4 2024 Earnings Call Transcript
Arcadia Biosciences, Inc (NASDAQ:RKDA ) Q4 2024 Results Conference Call March 20, 2025 4:30 PM ET Company Participants Mark Kawakami - Chief Financial Officer T.J. Schaefer - President & Chief Executive Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Operator Good...
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the fourth quarter and full year of 2024. “We are extremely pleased with the progress we made...
Arcadia Biosciences (RKDA) Announces Date of Fourth Quarter 2024 Financial Results and Business Highlights Conference Call
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the fourth quarter and full year of 2024 after market close on March 20,...
RKDA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Arcadia Biosciences, Inc. is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Arcadia Biosciences, Inc. (NASDAQ: RKDA) and Roosevelt Resources LP is fair to Arcadia shareholders. Upon closing of the proposed transaction, Arcadia shareholders are expected to own...
ARCADIA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Arcadia Biosciences, Inc. - RKDA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Arcadia Biosciences, Inc. (NasdaqCM: RKDA) and Roosevelt Resources LP. Pursuant to the terms of the...
Arcadia Biosciences to Merge With Roosevelt, Shares Surge 105%
RKDA inks deal with Roosevelt to become a new entity, Roosevelt Resources, with Roosevelt as the majority shareholder.